What is the primary problem TympaHealth is solving?

TympaHealth addresses the growing global burden of hearing loss, which the WHO predicts will affect 700 million people by 2050. Specifically, they solve the bottleneck of specialist-only care by providing a portable system that allows non-specialists in pharmacies or retail clinics to perform professional-grade ear assessments and wax removal.

How does the TympaHealth platform generate revenue for providers?

Slide 10 explicitly states the device 'drives revenue for the provider.' By enabling pharmacies and retail clinics to offer services like microsuction wax removal and hearing assessments—which previously required a hospital visit—providers can monetize a 30-minute clinical window that was previously unavailable to them.

What role does Artificial Intelligence play in their product?

AI is used for diagnostic support and predictive health. According to Slide 22, their algorithm identifies eardrum abnormalities with over 90% sensitivity. They are also working with UCL to correlate tympanic membrane changes with systemic conditions like diabetes and hypertension, similar to how the retina is used in diagnostics.

Does the deck include financial metrics or a specific funding ask?

The provided slides do not contain a specific 'Ask' slide detailing the $23M use of funds, nor do they show historical revenue or P&L projections. The narrative focuses on market opportunity, product capability, and data moats rather than unit economics.

Who is the target user for the TympaHealth device?

The target users are non-specialist healthcare professionals in 'any point of care setting,' such as pharmacies, retail environments, and provider clinics. The goal is to allow these professionals to become 'hearing health experts' through the use of their integrated hardware and remote review system.

TympaHealth Pitch Deck: All 27 Slides + Teardown

See all 27 slides of the TympaHealth pitch deck — a 2024 Series A deck — with a slide-by-slide teardown of what the deck does well and where it falls short.

TympaHealth’s Series A deck is a masterclass in positioning a medical device as a scalable platform. By focusing on the 'de-specialization' of ear care, the company demonstrates how their portable system allows non-specialists to perform complex procedures like microsuction and digital otoscopy in under 30 minutes. The deck leans heavily on clinical validation, citing the world’s largest bank of ear health data (>500k records) and an AI algorithm with over 90% sensitivity. While the deck lacks explicit financial projections or a detailed breakdown of the $23M ask in the provided slides, it su…

Key takeaways

The WHO estimates that by 2050, more than 700 million people globally will experience profound hearing loss (Slide 4).
TympaHealth positions hearing loss as the leading modifiable risk factor for dementia prevention (Slide 4).
The platform enables a full ear care appointment—including digital otoscopy, microsuction, and hearing assessment—in under 30 minutes (Slide 7).
The hardware is described as a 'uniquely designed, digital health device' that integrates three diagnostic systems into one portable unit (Slide 10).
The company claims to hold the world’s largest bank of ear and hearing health data with over 500,000 records (Slide 22).
Their AI algorithm identifies eardrum abnormalities with >90% sensitivity and specificity (Slide 22).
The leadership team features executives with backgrounds from Apple, Demant, and Meddbase (Slide 16).
The deck highlights a 'first-mover advantage' in newly created ear and hearing health markets through multiple sector deployment (Slide 19).

The Narrative: Moving Specialist Care to the High Street

TympaHealth’s Series A deck is built on a foundation of clinical necessity and market expansion. The London-based startup, as reported by Business Insider, raised $23M in 2024 to solve a specific logistical bottleneck in healthcare: the fact that ear and hearing care is traditionally locked behind expensive, hospital-based specialist appointments. The deck argues that by decentralizing this care, TympaHealth can address a massive global health crisis while creating a new revenue stream for retail healthcare providers.

Slide 1: The Hook and Validation

The title slide, Ear and Hearing Health Made Easy , immediately establishes the value proposition. Rather than focusing on the technical specifications of the device, it focuses on the outcome. The bottom of the slide is crowded with high-tier validation logos, including the ENTUK Winner of the Rowena Ryan ENT Prize , the IF Design Award 2021 , and the RSM Innovation in Otology Award . For a Series A company, this level of third-party clinical and design validation is a powerful signal of de-risked technology.

Slide 4: The Macro Problem

Slide 4 utilizes World Health Organization (WHO) data to frame the urgency of the mission. It notes that by 2050, 700 million people will experience profound hearing loss. Crucially, it links hearing loss to broader, high-cost health issues: it is the 'leading modifiable risk factor for prevention of dementia' and is strongly linked to falls and loneliness. By framing ear care as dementia prevention, TympaHealth elevates its product from a 'nice-to-have' wellness tool to a critical piece of preventative healthcare infrastructure.

Slide 7: The Opportunity and Workflow

This slide explains the 'how.' It introduces the 30 Minute Tympa Appointment . The graphic shows a linear pathway: Digital Otoscopy, Microsuction Wax Removal, Hearing Assessment, and Remote Review. The key takeaway here is that 'any professional' can become an expert. This is the core of their business model—labor arbitrage. By moving these tasks from a high-cost ENT specialist to a lower-cost pharmacy technician, they unlock massive efficiency in the healthcare system.

Slide 10 & 13: The Hardware and Software Platform

Slide 10 defines the platform as a 'uniquely designed, digital health device' that integrates three systems into one portable unit. Slide 13 provides a visual breakdown of the ecosystem. It isn't just a scope; it includes Integrated Machine Learning , Digital Records & Imaging , and a Remote Review & Diagnostics portal. This slide is critical because it justifies the 'SaaS' component of the business. The hardware is the Trojan horse that enables a continuous stream of data and remote consultation fees.

Slide 16: The Team

The 'Team of Experts' slide highlights four key leaders. Dr. John Maddison (CTO) is associated with Novai, Rob Stagg (CCO) with Meddbase, Nick Pattas (COO) with Apple, and Duncan Smith (CPO) with Demant. The inclusion of Apple and Demant (a global leader in hearing healthcare) is particularly strategic, suggesting the company has the operational expertise to scale consumer-grade hardware with medical-grade precision.

Slide 19 & 22: The Data Moat and Future Opportunities

Slide 19 mentions 'Multiple sector deployment with first-mover advantage.' This is expanded upon in Slide 22, which is perhaps the most important slide for a Series A investor. It claims Tympa holds the 'world’s largest bank of ear and hearing health data (>500k)' . In the age of AI, data is the ultimate moat. The slide notes their AI can identify abnormalities with >90% sensitivity and mentions ongoing research with UCL to use the ear drum as a diagnostic window for diabetes and hypertension. This transforms the company from a hearing aid screening tool into a multi-diagnostic platform.

What Works in the TympaHealth Deck

1. Clear Value Proposition for the Buyer: The deck explicitly mentions 'driving revenue for the provider' on Slide 10. In healthcare, clinical efficacy is rarely enough; you must show how the person buying the device makes their money back. By highlighting the 30-minute appointment window, they make the ROI calculation simple for pharmacy owners.

2. Massive Data Moat: Claiming the world's largest dataset of ear health (>500k records) is a significant competitive advantage. It suggests that even if a competitor builds a similar device, they will be years behind in training diagnostic AI models.

3. Strategic Comorbidity Linking: By connecting hearing loss to dementia and falls (Slide 4), TympaHealth taps into the largest cost centers for healthcare payers and governments. This makes their solution relevant to a much broader set of stakeholders than just audiologists.

What is Missing from the Provided Slides

1. Unit Economics: While the deck mentions revenue generation for providers, it does not disclose the cost of the hardware, the subscription fee for the SaaS platform, or the margins on the remote review service. Investors at the Series A stage typically require a clear view of the LTV/CAC ratio.

2. Competitive Landscape: The deck asserts a 'first-mover advantage' but does not provide a competitive matrix. There are other digital otoscopes and portable audiometry devices on the market; the deck fails to explicitly contrast TympaHealth against these incumbents or other startups.

3. Financial Projections and The Ask: The provided slides end with a brand-focused 'I Heart Tympa' slide (Slide 25). There is no slide detailing the specific use of the $23M raised, nor are there projections for market penetration or revenue growth over the next 3-5 years.

Founder Takeaways: How to Pitch a 'De-Specialization' Play

Focus on the 'Who,' not just the 'What': TympaHealth succeeds by showing that their product allows a less-expensive worker to do a more-expensive worker's job. If your startup involves decentralizing a professional service, your deck must emphasize the ease of use and the training support (as seen on Slide 13) that makes this transition possible.

Build a Data Narrative Early: Even if your AI isn't fully autonomous yet, showing that you are collecting a proprietary dataset (Slide 22) creates a 'winner-take-all' narrative. Investors want to see that your lead will grow over time, not shrink as competitors enter.

Use Third-Party Validation to Short-Cut Trust: In healthcare, founders often spend too much time explaining the science. TympaHealth uses a 'wall of logos' on Slide 1 to let the experts speak for them. If you have won industry awards or clinical prizes, put them on the front page to immediately establish authority.

Frequently asked questions

What is the primary problem TympaHealth is solving?: TympaHealth addresses the growing global burden of hearing loss, which the WHO predicts will affect 700 million people by 2050. Specifically, they solve the bottleneck of specialist-only care by providing a portable system that allows non-specialists in pharmacies or retail clinics to perform professional-grade ear assessments and wax removal.
How does the TympaHealth platform generate revenue for providers?: Slide 10 explicitly states the device 'drives revenue for the provider.' By enabling pharmacies and retail clinics to offer services like microsuction wax removal and hearing assessments—which previously required a hospital visit—providers can monetize a 30-minute clinical window that was previously unavailable to them.
What role does Artificial Intelligence play in their product?: AI is used for diagnostic support and predictive health. According to Slide 22, their algorithm identifies eardrum abnormalities with over 90% sensitivity. They are also working with UCL to correlate tympanic membrane changes with systemic conditions like diabetes and hypertension, similar to how the retina is used in diagnostics.
Does the deck include financial metrics or a specific funding ask?: The provided slides do not contain a specific 'Ask' slide detailing the $23M use of funds, nor do they show historical revenue or P&L projections. The narrative focuses on market opportunity, product capability, and data moats rather than unit economics.
Who is the target user for the TympaHealth device?: The target users are non-specialist healthcare professionals in 'any point of care setting,' such as pharmacies, retail environments, and provider clinics. The goal is to allow these professionals to become 'hearing health experts' through the use of their integrated hardware and remote review system.

Cover slide of the TympaHealth pitch deck — Series A 2024 — TympaHealth pitch deck, slide 1 (2024)

TympaHealth pitch deck: the facts

Company: TympaHealth
Year: 2024
Stage: Series A
Slides: 27
Sector: Healthcare
Deck type: Investor Presentation
Outcome: $23M Raised
Headquarters: London, UK

TympaHealth pitch deck PDF

The full TympaHealth deck is embedded on this page and can be read slide by slide in the browser — no download or account required. Each slide is covered in the breakdown above.

What the TympaHealth pitch deck was used for

This deck is TympaHealth’s 2024 **Series A** fundraising presentation for its ear and hearing health platform, associated with the $23M Series A round announced in April 2023 and logged as completed in February 2024.[4][5][7][8][14][15] The company provides a comprehensive, tech-enabled solution that lets non‑specialist clinicians deliver ear examinations, wax removal and hearing screening in community settings using handheld hardware plus software and remote specialist support.[5][6][11][12][15] The Series A funding, led by Octopus Ventures with several co‑investors, was raised to expand access to TympaHealth’s solution, scale in the UK and enter international markets including the US.[4][5][7][8][14] The 27‑slide deck likely focuses on how moving specialist ear care into pharmacies and other local sites creates access, efficiency and cost benefits for healthcare systems and payers, supported by a hardware‑plus‑SaaS recurring revenue model.

Business model: Hardware-plus-SaaS ear and hearing health platform delivered in community settings (pharmacies, care homes, clinics), combining handheld examination devices, software, training and remote specialist support.[6][11][12][15]

Raised: $23M Series A.[1][2][3][4][5][7][8][14][15]
Lead investor: Octopus Ventures.[3][4][5][7][8][14]
Investors: Octopus Ventures (lead).[3][4][5][7][8][14], Dara Capital.[1][3][5][7][8][14], Rezayat Investments.[1][3][5][7][8][14], Bob Davis (angel).[1][3][5][7][8][14], Jeff Leerink (angel).[1][3][5][7][8][14], Existing investors from prior rounds, including KHP MedTech Innovations (confirmed at seed stage).[8][10]
Founders: Dr Krishan Ramdoo[5][8]
Headquarters: London, United Kingdom.[4][6][11][13][15]
Industry: Healthcare; hearing and ear health diagnostics and services.[4][5][6][11][12][15]

Round: Series A (later-stage VC, revenue-generating). [4][5][14][15]

Year: 2024 (deal completion recorded as 13 February 2024, with funding widely announced April 2023).[4][5][8][14][15]

Total funding: At least $31M disclosed: $8M seed round plus $23M Series A.[2][10][15]

Use of funds as presented: Expand access to TympaHealth’s tech-enabled hearing assessment and diagnostic solution, scale deployments in the UK, and support international expansion including US market entry.[1][4][5][7][8]

What happened after the TympaHealth deck

Following its $8M seed round, TympaHealth closed a $23M Series A led by Octopus Ventures to scale its comprehensive ear and hearing health platform and expand internationally, with public sources indicating the round completed in early 2024 and the company operating as a revenue-generating UK-based healthcare technology provider.[2][3][4][5][7][8][10][14][15]

Closed a $23M Series A funding round led by Octopus Ventures, with participation from Dara Capital, Rezayat Investments
Recorded the Series A as a later-stage VC deal completed on 13 February 2024, with the company described as generating r
Previously raised a $8M seed round to support expansion across the UK, Europe and US markets and to build the leadership
Expanded deployment of its comprehensive ear and hearing health solution across pharmacies and care homes, positioning t

What the TympaHealth deck got right

Integrated, end-to-end solution for ear and hearing care. TympaHealth offers a **fully comprehensive ear and hearing health solution** that integrates handheld diagnostic hardware, software, training, remote ENT/audiologist support and referral pathways, enabling community providers to deliver specialist-grade care.[5][6][11][12][15]
Strong fit with community-based healthcare delivery. The platform is explicitly designed for **pharmacies, care homes and clinics**, moving hearing assessments and wax removal out of hospital-based specialist settings and into local community environments, which aligns with health system trends toward decentralised care.[6][11][12][15]
Hardware-plus-SaaS business model with recurring revenue potential. TympaHealth’s **hardware-plus-SaaS model** provides recurring revenue potential from software and service subscriptions layered on top of device deployments and accredited training.[5][6][11][12][15]
Strong investor backing and funding history. The company secured a **$23M oversubscribed Series A** led by Octopus Ventures with multiple co‑investors, following an $8M seed round, signalling strong investor confidence in the market opportunity and team.[1][2][3][4][5][7][8][10][14][15]
Compelling clinical workflow improvements. External descriptions highlight that TympaHealth enables clinicians to perform **digital otoscopy, micro-suction wax removal and hearing screening in a single appointment**, offering clear workflow simplification and potential efficiency gains.[5][6][15]

What could have been stronger

Limited externally visible detail on revenue mix and unit economics. Public sources confirm the Series A amount, lead investor and participating investors, but do not detail unit economics, margins, or specific SaaS pricing, so the deck likely leaves investors with limited externally verifiable information on revenue quality (e.g., proportion of recurring SaaS fees versus one‑off hardware and training).[3][4][5][7][8][14][15]
Traction and deployment metrics are not well documented in public materials. While TympaHealth is presented as a comprehensive solution for pharmacies, care homes and clinics, public materials focus more on product capabilities than on quantified adoption metrics (number of installed sites, exam volumes, churn rates), suggesting the deck may under‑document traction relative to investor expectations. [6][11][12][15]
Go-to-market and regulatory strategy outside the UK appears thinly evidenced. External coverage highlights international expansion (including US market entry and FDA registration) as a key use of funds, but provides little detail on regulatory strategy, reimbursement pathways or competitive positioning in each geography, implying the deck may only partially address go‑to‑market risk outside the UK.[4][5][7][8]
Limited published clinical and economic outcomes to support impact claims. PitchBook and press reports describe the Series A as later-stage VC with generating revenue status, but they do not specify clinical outcome data (e.g., impact on waiting times, cost savings, or hearing loss detection rates), which could weaken the clinical and economic evidence case if similarly underdeveloped in the deck.[5][10][15]

How an investor would read this deck

What draws attention

Verification of recurring revenue streams from the SaaS layer versus hardware sales, including pricing, contract lengths and renewal rates.[5][6][11][12][15]
Evidence of scalable demand from pharmacies, care homes and clinics, with clear adoption metrics, cohort behavior and funnel benchmarks across UK and early international markets.[6][11][12][15]
Clarity on regulatory status (including FDA registration), reimbursement, and channel partnerships in the US and other target geographies mentioned in the Series A use-of-funds narrative.[4][5][7][8]
Strength and defensibility of TympaHealth’s technology stack (hardware integration, imaging, AI software) relative to incumbent audiology and ENT solutions.[5][6][11][12][15]

Risks that stand out

Dependence on adoption by community healthcare settings (pharmacies, care homes, clinics) could slow growth if behavior change or staffing constraints limit uptake, despite the product’s comprehensive design.[6][11][12][15]
International expansion, particularly into the US, introduces regulatory, reimbursement and competitive risks that may not be fully mitigated by the FDA registration alone.[4][5][7][8]
A hardware-plus-SaaS model may require significant ongoing capital for device manufacturing, training and support, which can compress margins if SaaS penetration is not sufficiently high.[5][6][11][12][15]

Questions this deck invites

What portion of current revenues comes from recurring SaaS and service fees versus one-time hardware and training, and how has this mix evolved since closing the Series A round?[5][6][11][12][15]
How many active customer sites (pharmacies, care homes, clinics) are live with TympaHealth today, and what are the average examination volumes, renewal rates and churn metrics by cohort?[6][11][12][15]
What specific regulatory approvals and registrations (including FDA) has TympaHealth obtained in each target market, and what is the roadmap for reimbursement coverage and payer contracts?[4][5][7][8]
How does TympaHealth’s solution compare to competing hearing diagnostics and wax removal offerings in terms of accuracy, workflow integration, cost per exam and patient outcomes?[5][6][11][12][15]
What milestones and KPIs were tied to the $23M Series A funding (e.g., US launches, product iterations, team hires), and which of these have been achieved post‑fundraise?[4][5][7][8][15]

What founders can take from the TympaHealth deck

A clearly articulated hardware-plus-SaaS model in a niche clinical domain (ear and hearing health) can attract substantial Series A capital when paired with an integrated workflow and remote specialist support.[5][6][11][12][15]
Positioning a solution as an enabler of community-based care—pharmacies, care homes, local clinics—helps frame the business as a healthcare infrastructure play rather than a single-product device company.[6][11][12][15]
Using funding announcements and press to emphasize oversubscription and a mix of institutional and strategic angel investors can strengthen perceived momentum around a Series A raise.[3][4][5][7][8][14]
Connecting product capabilities (digital otoscopy, wax removal, hearing screening) into a single appointment narrative resonates with health system priorities around efficiency and patient throughput.[5][6][11][12][15]
Explicitly tying use of funds to international expansion and market entry (e.g., UK scale plus US launch) provides a clear growth story, but it must be backed by credible regulatory and go‑to‑market plans.[4][5][7][8]

TympaHealth pitch deck: common questions

What does TympaHealth do?

TympaHealth is a London-based hearing and ear health startup that has developed a handheld examination kit and integrated software platform allowing clinicians in community settings (such as pharmacies and care homes) to perform high-definition digital otoscopy, micro‑suction wax removal and hearing screening in a single appointment, with remote specialist support.[5][6][11][12][15]

How much did TympaHealth raise in its Series A and who invested?

TympaHealth raised **$23M in a Series A round** led by Octopus Ventures, with participation from Dara Capital, Rezayat Investments and angel investors Bob Davis and Jeff Leerink, alongside existing investors, to expand and internationalize its ear and hearing health platform.[3][4][5][7][8][14] The raise is recorded as a later-stage VC (Series A) deal completed on 13 February 2024.[15]

What was the purpose of TympaHealth’s Series A funding round?

According to funding announcements and company materials, TympaHealth’s Series A funds are being used to expand access to its hearing assessment and diagnostic solution, grow its presence in UK community healthcare settings, and support international expansion including entry into the US market where the product has FDA registration.[4][5][7][8]

Who are TympaHealth’s primary users and customers?

TympaHealth’s platform is designed for use in pharmacies, care homes and audiology clinics, enabling allied healthcare professionals to deliver ear examinations, wax removal and hearing screening in local community settings instead of hospital-based specialist clinics.[6][11][12][15]

What is unique about TympaHealth’s product offering compared to traditional hearing services?

Reports describe TympaHealth’s solution as a fully comprehensive ear and hearing health platform that combines handheld diagnostic hardware, software, accredited training, access to ENT and audiologist support, and referral pathways to specialist care, with deployments across pharmacies and care homes.[6][11][12][15] This integrated model positions TympaHealth as an infrastructure provider for hearing care rather than a single-device company.